Synlogic Inc (NASDAQ:SYBX) – Equities researchers at Svb Leerink raised their Q1 2019 EPS estimates for shares of Synlogic in a research note issued to investors on Wednesday, March 13th. Svb Leerink analyst J. Schwartz now forecasts that the biotechnology company will earn ($0.51) per share for the quarter, up from their prior forecast of ($0.58). Svb Leerink also issued estimates for Synlogic’s Q2 2019 earnings at ($0.52) EPS, Q3 2019 earnings at ($0.54) EPS, Q4 2019 earnings at ($0.56) EPS, FY2019 earnings at ($2.13) EPS and FY2020 earnings at ($1.98) EPS.
Several other analysts have also issued reports on SYBX. Zacks Investment Research raised Synlogic from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a research note on Saturday, November 17th. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 target price on shares of Synlogic in a research note on Tuesday. HC Wainwright set a $20.00 price objective on Synlogic and gave the company a “buy” rating in a research note on Monday, December 10th. ValuEngine lowered Synlogic from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, BTIG Research began coverage on Synlogic in a research note on Tuesday, February 12th. They set a “buy” rating and a $22.00 price objective for the company. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $18.59.
Shares of SYBX opened at $7.73 on Friday. The company has a market capitalization of $197.99 million, a price-to-earnings ratio of -3.81 and a beta of 2.38. Synlogic has a 1 year low of $5.75 and a 1 year high of $14.59.
Synlogic (NASDAQ:SYBX) last issued its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.09. The business had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.24 million. Synlogic had a negative return on equity of 35.58% and a negative net margin of 1,922.02%.
In other Synlogic news, insider Paul Francis Miller sold 9,000 shares of the stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $9.75, for a total value of $87,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 23.30% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in Synlogic by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 155,161 shares of the biotechnology company’s stock valued at $1,087,000 after acquiring an additional 16,591 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Synlogic by 50.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 316,656 shares of the biotechnology company’s stock valued at $2,220,000 after acquiring an additional 105,628 shares during the last quarter. Northern Trust Corp raised its holdings in Synlogic by 1.2% in the 4th quarter. Northern Trust Corp now owns 167,135 shares of the biotechnology company’s stock valued at $1,172,000 after acquiring an additional 2,005 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Synlogic by 12.1% in the 4th quarter. Bank of New York Mellon Corp now owns 56,774 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 6,129 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in Synlogic by 33.4% in the 4th quarter. BlackRock Inc. now owns 1,248,355 shares of the biotechnology company’s stock valued at $8,750,000 after acquiring an additional 312,398 shares during the last quarter. Institutional investors and hedge funds own 84.85% of the company’s stock.
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Recommended Story: Dividend Achievers
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.